ASCO Lung Cancer Highlights, Part 6: Predicting Benefit of Chemotherapy vs. EGFR Inhibitor Therapy in Second Line (audio)
- Author
- cancerGRACE - H. Jack West, MD
- Published
- Fri 16 Aug 2013
- Episode Link
- http://cancergrace.libsyn.com/asco-lung-cancer-highlights-part-6-predicting-benefit-of-chemotherapy-vs-egfr-inhibitor-therapy-in-second-line-audio
Dr. David Gerber, University of Texas-Southwestern, reviews the results of the PROSE study of the Veristrat serum proteomics test to predict benefit of chemo or EGFR inhibitor for second line treatment of advanced lung cancer.
